Literature DB >> 7995799

Fragile X syndrome in a normal IQ male with learning and emotional problems.

S A Merenstein1, V Shyu, W E Sobesky, L Staley, E Berry-Kravis, D L Nelson, K A Lugenbeel, A K Taylor, B F Pennington, R J Hagerman.   

Abstract

The present case study features an adult male who was diagnosed with fragile X syndrome after the identification of this syndrome in his more affected brother. The patient presented with a Full Scale IQ within the broad range of normal and has been diagnosed with a schizotypal personality disorder. He shows significant deficits in the social and emotional aspects of daily life, but has striking cognitive strengths relating to reading and vocabulary as compared to most males affected with fragile X syndrome. DNA testing of blood leukocytes revealed that he has a fully expanded FMR1 CGG repeat mutation associated with almost complete lack of methylation. Protein studies demonstrate a limited production of FMRP, the protein produced by the FMR1 gene. It is believed that the near absence of methylation of the fully expanded mutation and the resultant expression of the FMR1 protein is responsible for the strong cognitive abilities of this fragile X patient.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995799     DOI: 10.1097/00004583-199411000-00014

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  9 in total

1.  FMR1 fully expanded mutation with minimal methylation in a high functioning fragile X male.

Authors:  Z Wang; A K Taylor; J A Bridge
Journal:  J Med Genet       Date:  1996-05       Impact factor: 6.318

2.  Don't miss patients with atypical FMR1 mutations: dysmorphism and clinical features in a boy with a partially methylated FMR1 full mutation.

Authors:  Edda Haberlandt; Sibylle Zotter; Martina Witsch-Baumgartner; Johannes Zschocke; Dieter Kotzot
Journal:  Eur J Pediatr       Date:  2014-07-17       Impact factor: 3.183

3.  Unusual mutations in high functioning fragile X males: apparent instability of expanded unmethylated CGG repeats.

Authors:  D Wöhrle; U Salat; D Gläser; J Mücke; M Meisel-Stosiek; D Schindler; W Vogel; P Steinbach
Journal:  J Med Genet       Date:  1998-02       Impact factor: 6.318

Review 4.  Fragile X syndrome. Molecular and clinical insights and treatment issues.

Authors:  R J Hagerman
Journal:  West J Med       Date:  1997-02

5.  Hypomethylation of an expanded FMR1 allele is not associated with a global DNA methylation defect.

Authors:  R W Burman; P A Yates; L D Green; P B Jacky; M S Turker; B W Popovich
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

6.  Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency.

Authors:  Sebastien Jacquemont; Stefanie Birnbaum; Silke Redler; Peter Steinbach; Valérie Biancalana
Journal:  Eur J Hum Genet       Date:  2011-05-04       Impact factor: 4.246

7.  Clinical and molecular implications of mosaicism in FMR1 full mutations.

Authors:  Dalyir Pretto; Carolyn M Yrigollen; Hiu-Tung Tang; John Williamson; Glenda Espinal; Chris K Iwahashi; Blythe Durbin-Johnson; Randi J Hagerman; Paul J Hagerman; Flora Tassone
Journal:  Front Genet       Date:  2014-09-17       Impact factor: 4.599

8.  Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.

Authors:  Sarah Brasa; Arne Mueller; Sébastien Jacquemont; Florian Hahne; Izabela Rozenberg; Thomas Peters; Yunsheng He; Christine McCormack; Fabrizio Gasparini; Salah-Dine Chibout; Olivier Grenet; Jonathan Moggs; Baltazar Gomez-Mancilla; Rémi Terranova
Journal:  Clin Epigenetics       Date:  2016-02-05       Impact factor: 6.551

9.  Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions.

Authors:  Kyoungmi Kim; David Hessl; Jamie L Randol; Glenda M Espinal; Andrea Schneider; Dragana Protic; Elber Yuksel Aydin; Randi J Hagerman; Paul J Hagerman
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.